Lyell Immunopharma's 15min chart sees KDJ Golden Cross, bullish Marubozu pattern.

Lyell Immunopharma's 15-minute chart has exhibited a KDJ Golden Cross, coupled with a Bullish Marubozu at 09/18/2025 14:45. This signifies a shift in the momentum of the stock price towards a more positive direction, with potential for further upward movement. The control of the market is currently in the hands of buyers, and it is likely that bullish momentum will continue.

Lyell Immunopharma has announced the departure of its Chief Financial Officer, Charles Newton, effective October 31, 2025. Newton will also step down as the principal accounting officer, as reported by Connor Hart of MarketWatch Lyell Immunopharma Launches CFO Search After Newton Departs^[1]. The company is currently searching for a replacement for these roles.

The announcement comes as Lyell Immunopharma continues to navigate its strategic and financial landscape. Recently, the company secured a $100 million private placement to fund clinical milestones Lyell Immunopharma Inc.^[2]. This funding round is part of the company's ongoing efforts to advance its cell-based immunotherapies for human diseases.

The departure of Newton follows a series of strategic moves by the company, including the initiation of a Phase 3 head-to-head CAR T-cell therapy trial . These initiatives aim to bolster the company's pipeline and position it for future growth.

In the market, Lyell Immunopharma's stock has exhibited a KDJ Golden Cross coupled with a Bullish Marubozu on September 18, 2025, at 14:45 . This technical indicator suggests a shift in the stock's momentum towards a more positive direction, with potential for further upward movement. The control of the market is currently in the hands of buyers, indicating a bullish trend.

The departure of Newton and the ongoing strategic initiatives highlight Lyell Immunopharma's commitment to its growth trajectory. As the company continues to make progress in its clinical trials and secure funding, investors should monitor the market's reaction to these developments.